| Objective/purpose: |
Collect
supportive and pivotal data needed to establish the effectiveness
of oxytetracycline (OTC) to mark otoliths in a variety of fish
species. |
| Drug name: |
Terramycin-343 |
| Source of drug: |
Pfizer,
Inc. |
| Address: |
1107 South
291 Highway
Lee's Summit, MO 64081 |
| Contact: |
Phone:
816-524-5580; Fax: 816-525-7360 |
| Target
pathogen(s): |
Not Applicable |
| Method
of administration: |
Immersion:
standing-bath treatment only |
| Treatment
dosage: |
500 milligrams
OTC per liter |
| Treatment
regimen: |
6-hour
treatment (all species) Single treatment only |
| Withdrawal
period: |
None. Fish
may be released immediately following treatment. |
Required
test parameters:
As a result of the three recent OTC-marking approvals, this INAD has been officially terminated. To view this fact sheet, select "Print this drug fact sheet" on the left side of this screen. |
Investigator
must collect mark retention and mortality data. Investigator
should also report general fish behavior and any adverse effects
relating to treatment. |
| Limitations
or restrictions on use: |
Treatment
is restricted to fish having a body weight of 2 grams or less.
Investigator
must follow all instructions in the Study Protocol for INAD
9033 regarding drug acquisition and handling, fish treatment
and disposition, and data reporting requirements.
Drug
discharge must be in compliance with local NPDES permitting
requirements. |
| Required
INAD fee: |
None |
| AADAP
contact for other information: |
Ms.
Bonnie Johnson, FWS - AADAP
Phone: 406-587-9265 ext. 136
Fax: 406-582-0242
bonnie_johnson@fws.gov |
| Disclaimer: |
Product and company names mentioned in this website, or mentioned in materials accessed via this website, are for informational purposes only. The mention of such does not imply endorsement by the Aquatic Animal Drug Approval Partnership, the U.S. Fish & Wildlife Service or any other organization of the U.S. Government. |
|
